Abstract: Objective : To evaluate the curative effect and the toxicities of intraperitoneal hyperthermic chemotherapycombined with FOLFOX4 and venous chemotherapy for advanced gastric carcinoma after non-radicalsurgery. Methods : A total of 65 patients with advanced gastric cancer who underwent non-radical surgery fromJanuary 2002 to February 2005 were randomly classified into two groups. Group 1 patients were treated withboth intraperitoneal chemotherapy (DDP 60~80mg/m², MMC 4~6mg/m², and 5-Fu 0.75/m², every two weeks)and intravenous chemotherapy (FOLFOX4). Patients in Group 2 received only intravenous chemotherapy ofDF (5-Fu 0.5/m²d1~3, LV 0.1/m²d1~3, DDP 30~40mg/m 2 d1~3, or 5-Fu 3.0 i.v. drip by infusion pump in 48hours, every 3-4 weeks). Results : The 1-, 2-, and 3-year survival rates were 83.3% (28/34), 58.8% (20/34),and 44.1% (14/34) in Group 1, and 83.9% (26/31), 29.0% (9/31), and 16.1% (5/31) in Group 2. There was noremarkable difference in the 1-year survival rate between the two groups (P>0.05). Significant differenceswere found in the 2- and 3-year survival rates between the two groups (P<0.05). No statistical significancewas found in the toxic reactions between the two groups (P<0.05). The complications in the two groups includ-ed abdominal discomfort, abdominal distension, diarrhea and constipation. Conclusion : Intraperitonealchemotherapy combined with intravenous FOLFOX4 chemotherapy is an advisable treatment for patients withadvanced gastric cancer who have undergone non-radical surgery.